Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Kuper

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Arthritis and Rheumatism|June 8, 2011
Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort studyMarloes Vermeer, Hillechiena H Kuper, Monique Hoekstra, et al.
Annals of the Rheumatic Diseases|January 3, 2012
A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registryLydia G Schipper, Marloes Vermeer, Hillechiena H Kuper, et al.
Arthritis Care & Research|February 26, 2013
Sustained beneficial effects of a protocolized treat-to-target strategy in very early rheumatoid arthritis: three-year results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohortM Vermeer, H H Kuper, H J Bernelot Moens, et al.
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)|July 20, 2002
Correlates of pregnancy oestrogen, progesterone and sex hormone-binding globulin in the USA and ChinaJ Wuu, S Hellerstein, L Lipworth, et al.
Rheumatology (Oxford, England)|February 4, 2012
The provisional ACR/EULAR definition of remission in RA: a comment on the patient global assessment criterionMarloes Vermeer, Hillechiena H Kuper, Arie E van der Bijl, et al.
Arthritis Care & Research|May 28, 2010
Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practiceM Blom, W Kievit, H H Kuper, et al.
Arthritis Research & Therapy|March 10, 2016
Initial combination therapy versus step-up therapy in treatment to the target of remission in daily clinical practice in early rheumatoid arthritis patients: results from the DREAM registryL M M Steunebrink, G A Versteeg, H E Vonkeman, et al.
The Journal of Rheumatology|September 3, 2009
The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritisMarlies Blom, Wietske Kievit, Jaap Fransen, et al.
BMC Musculoskeletal Disorders|December 17, 2013
Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registryMarloes Vermeer, Wietske Kievit, Hillechiena H Kuper, et al.
Annals of the Rheumatic Diseases|July 16, 2008
Evaluating guidelines on continuation of anti-tumour necrosis factor treatment after 3 months: clinical effectiveness and costs of observed care and different alternative strategiesW Kievit, J Fransen, E M Adang, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Arthritis and Rheumatism|June 8, 2011
Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort studyMarloes Vermeer, Hillechiena H Kuper, Monique Hoekstra, et al.
Annals of the Rheumatic Diseases|January 3, 2012
A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registryLydia G Schipper, Marloes Vermeer, Hillechiena H Kuper, et al.
Arthritis Care & Research|February 26, 2013
Sustained beneficial effects of a protocolized treat-to-target strategy in very early rheumatoid arthritis: three-year results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohortM Vermeer, H H Kuper, H J Bernelot Moens, et al.
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)|July 20, 2002
Correlates of pregnancy oestrogen, progesterone and sex hormone-binding globulin in the USA and ChinaJ Wuu, S Hellerstein, L Lipworth, et al.
Rheumatology (Oxford, England)|February 4, 2012
The provisional ACR/EULAR definition of remission in RA: a comment on the patient global assessment criterionMarloes Vermeer, Hillechiena H Kuper, Arie E van der Bijl, et al.
Arthritis Care & Research|May 28, 2010
Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practiceM Blom, W Kievit, H H Kuper, et al.
Arthritis Research & Therapy|March 10, 2016
Initial combination therapy versus step-up therapy in treatment to the target of remission in daily clinical practice in early rheumatoid arthritis patients: results from the DREAM registryL M M Steunebrink, G A Versteeg, H E Vonkeman, et al.
The Journal of Rheumatology|September 3, 2009
The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritisMarlies Blom, Wietske Kievit, Jaap Fransen, et al.
BMC Musculoskeletal Disorders|December 17, 2013
Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registryMarloes Vermeer, Wietske Kievit, Hillechiena H Kuper, et al.
Annals of the Rheumatic Diseases|July 16, 2008
Evaluating guidelines on continuation of anti-tumour necrosis factor treatment after 3 months: clinical effectiveness and costs of observed care and different alternative strategiesW Kievit, J Fransen, E M Adang, et al.
Pageof 7